Can anyone challenge Hewlett-Packard's lead in the ultrasound market? GE is trying, supplementing its own effort with this deal which essentially brings it the old Diasonics business, once one of the leaders in ultrasound. The Diasonics technology, purchased from Elbit, should get a boost from GE's strong reputation among customers, while GE will benefit from a strong, dedicated selling presence.
Can anyone challenge Hewlett-Packard Co. in ultrasound? Elbit Ltd.'s sale of Diasonics Vingmed Ultrasound Ltd. , which it bought from Diasonics a couple of years ago, to General Electric Co. 's GE Medical Systems division suggests you can, but the game is not for the faint of heart [See Deal].
Diasonics' own efforts to build a multi-modality imaging business in the mid 1980s to challenge the likes of GE crashed...
During Q2, biopharma merger and acquisition deal value reached $24.6bn and drew in $60.7bn in potential deal value from alliances. Device company M&A values reached $223m, while in vitro diagnostics and research tools players’ M&A activity totaled $802m.
Facing rising costs and tighter regulations, PBMs and insurers are accelerating the shift to value-based drug coverage, demanding stronger proof of therapeutic and economic benefit from pharma.
Akelos is developing a first-in-class, non-addictive HCN1 inhibitor for peripheral neuropathic pain, based on anesthesiology research from Weill Cornell. The compound is designed to avoid the brain and heart, and has shown strong preclinical efficacy and safety with NIH backed development underway.
